-
Sort By
-
Newest
-
Newest
-
Oldest
-
All Categories
-
All Categories
-
Analysis
-
Asset management
-
Economics
-
Retirement
-
Value proposition
The ATO delivered some positive news, approving fractional property investment platform Domacom’s’ application to broaden the use of the $300,000 downsizer contribution.
Company reporting season is in its final stretch with roughly two-thirds of the ASX 200 having reported and another +40 companies still to go.
Currencies are the closest cousin to this age cohort in investment markets.
Just when you thought it was over. Coronavirus strikes again.
Treasurer Frydenberg provided his long-awaited budget update, which was just that an update, offering little in the way of guidance into the future. The Government are predicting unemployment will peak at 9.25% across the country, with ballooning deficits adding $250 billion to the debt pile.
The ASX 200 (ASX:XJO) finished off its lows for the day, falling 1.3%, as both Victoria and several US states hit record COVID-19 case levels, denting market sentiment.
Despite an increasing chorus of experts suggesting the technology sector has moved beyond reasonable levels, the rally continues. The ASX 200 (ASX:XJO) added 2.6%, hitting a six week high, with a 5.7% rally in the IT sector among the largest contributors.
A nascent asset class is emerging on the back of the roll out of the National Disability Insurance Scheme (NDIS). NDIS is a welfare support scheme of the Australian Government that funds costs associated with disability.
The ASX 200 (ASX:XJO) continued its recent weakness, falling 0.5% on Monday, as concerns of a secondary outbreak in NSW and escalating deaths in the US hit investor confidence.
Sideways….a weak opening ahead It was another bumpy, albeit positive, week for markets with the ASX 200 (ASX:XJO) gaining 0.4% on Friday and finishing around 2.0% higher for the week. The primary driver remained Australia’s main recovery hope, commodity exports, with the materials sector finishing 4.2% as the iron ore price remained above USD$115 per…
The ‘Vaccine’ rally was short-lived with a swathe of economic data sending the ASX 200 (ASX:XJO) 0.7% lower on Thursday.
The ASX 200 joined the global sharemarket rally, adding 1.9%, after healthcare US biotech company Moderna Inc. (NASDAQ:MRNA) announced positive results from their Phase 1 trial of a potential COVID-19 treatment.
